Statement: none of the individual aes recorded in the primary trial affect more than 0.1 of the population.
Primary_evidence: Adverse Events 1:   Total: 18/100 (18.00%)   Anaemia * 4/100 (4.00%)   Febrile neutropenia * 3/100 (3.00%)   Neutropenia * 1/100 (1.00%)   Pancytopenia * 0/100 (0.00%)   Thrombocytopenia * 1/100 (1.00%)   Acute coronary syndrome * 1/100 (1.00%)   Stress cardiomyopathy * 0/100 (0.00%)   Abdominal pain * 0/100 (0.00%)   Abdominal pain upper * 0/100 (0.00%)   Ascites * 1/100 (1.00%) Adverse Events 2:   Total: 45/152 (29.61%)   Anaemia * 0/152 (0.00%)   Febrile neutropenia * 3/152 (1.97%)   Neutropenia * 1/152 (0.66%)   Pancytopenia * 1/152 (0.66%)   Thrombocytopenia * 0/152 (0.00%)   Acute coronary syndrome * 0/152 (0.00%)   Stress cardiomyopathy * 1/152 (0.66%)   Abdominal pain * 2/152 (1.32%)   Abdominal pain upper * 2/152 (1.32%)   Ascites * 0/152 (0.00%)